T
Tear Film Innovations
An early-stage company developing break-through products for the treatment of evaporative dry eye and related syndromes
About Tear Film Innovations
Tear Film Innovations (TFI), established in 2012 by Brian Kelleher and Kabir Gambhir, is a medical device company focused on treatments for evaporative dry eye disease. The company operates in the ocular health market, providing solutions for eye care professionals to treat Meibomian Gland Dysfunction (MGD), the primary cause of dry eye. TFI's business model centers on the sale of its proprietary iLux device and associated disposable components to ophthalmologists and optometrists.
The company's journey began with the in-house invention and development of its core technology by its founders. A significant milestone was achieved in December 2017 when the iLux device received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This was followed by a successful Series A funding round of $9.22 million in November 2017 and a Series B round of $8.5 million in May 2018, led by investors including Visionary Ventures and Bluestem Capital, bringing total funding to $17.7 million. The commercial launch of the iLux system occurred in May 2018. The company's trajectory culminated in its acquisition by Alcon, a global leader in eye care, in December 2018, which aimed to expand TFI's technology to a broader global market.
TFI's flagship product, the iLux System, is a handheld, portable device used by practitioners for in-office treatment of MGD. The device works by applying controlled, light-based heat to the eyelids via disposable silicone pads, melting the hardened oils blocking the meibomian glands. A key feature is the integrated magnifying lens, allowing the clinician to observe the gland orifices and apply manually-controlled compression to express the melted blockages. This process is designed to be completed in a few minutes per treatment zone, offering a tailored procedure for each patient's needs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2018 | $8.5M | $34M | Visionary Ventures · Bluestem Capital | — |
| SERIES A✓Equity / VC | Nov 2017 | $9M | $36M | Tigris Capital · Tigris Ventures · Visionary Ventures | — |
Growth signals
Latest recorded traffic for Tear Film Innovations is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tear Film Innovations in the San Diego ecosystem
The Tear Film Innovations office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Tigris Ventures- VVVisionary Ventures
Tigris Capital
Bluestem Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tear Film Innovations on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tear Film Innovations’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









